Systemically administered drugs typically accumulate in the liver, and since HK2 is predominantly expressed in HCC, even modest doses of HK2 inhibitors can specifically target tumor cells with minimal impact on normal liver cells.17 The gene discussed is HK2; the disease is hepatocellular carcinoma.